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Shortly after Kono and associates1 reported their findingsconcerning the role of vascular endothelial growth factor(VEGF) gene expression in the development of cardiacmyxomas, we had the opportunity to assay plasma VEGF
before and after surgery in a 31-year-old black woman with multi-
centric recurring myxomas. At the age of 10 years, she had under-
gone excision of a left atrial myxoma. In the following decade, she
had 4 more operations with excision of 19 myxomas. The tumors
(9 on the right side and 10 on the left side), occurring at widely
separated and random sites within both atria and on the tricuspid
and mitral valves, appeared to develop de novo without invasion of
surrounding tissue. The sizes ranged from a “nodule” to 3 × 4 cm,
and the histologic features, by both light and electron microscopy,
were typical for myxoma. Now, 12 years after her fifth heart oper-
ation, the tumor recurred and she underwent a sixth operation. We
report our observations.
Methods 
Three tumors were resected. The largest (7.0 × 4.9 × 1.2 cm) arose
from the floor of the right atrium between the inferior vena cava
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and the os of the coronary sinus; a second tumor (4.0 × 2.0 × 2.5
cm) was attached to the ventricular septum 1 to 2 cm below the
pulmonary valve; and the third and smallest (0.7 × 0.6 × 0.2 cm)
arose from the dome of the left atrium. Blood for VEGF assay was
collected 2 to 3 hours before the operation and then 2 days, 51⁄2
weeks, and 6 months after the operation.
Plasma concentration of VEGF was compared with that of 4
men aged 41 ± 9 years, weighing 77 ± 16 kg, who had normal
blood pressure and who presumably were free of cardiovascular
disease, peripheral vascular disease, and malignancy. 
The samples were collected with ethylenediaminetetraacetic
acid, immediately centrifuged, and the plasma was stored at
–70°C. The plasma concentration was determined by means of
sandwich enzyme-linked immunosorbent assay (R&D Systems,
Minneapolis, Minn).2
This study was conducted in accordance with the guidelines of
the Institutional Review Board of The University of Mississippi
Medical Center. The subject of this study gave informed consent.
Results
There was a marked fall in the VEGF level after the operation.
From a preoperative level of 83.1 pg/mL, it fell to 23.4 pg/mL at 2
days, 20.7 pg/mL at 51⁄2 weeks, and 32.0 pg/mL at 6 months. The
plasma concentration of VEGF in 4 healthy subjects (mean ± SD)
was 40.0 ± 26.4 pg/mL.
Discussion
VEGF, also known as vascular permeability factor, is a glycopro-
tein that initiates mitosis of endothelial cells. Although an expect-
ed plasma constituent, there is no established “normal” concentra-
tion, and from our observations the range is wide. The patient’s
plasma level before removal of the tumors was 25% above the
highest found in the 4 healthy men; although “high,” it is not con-
clusive. However, the marked fall (from 83.1 to 23.4 pg/mL) noted
2 days after the operation and persisting at 51⁄2 weeks and at 6
months suggests the level was heightened as a consequence of
active expression of VEGF limited to the tumor; that supposition is
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solitary myxoma. Otherwise, little more can be made of this single
case. However, should it be established that a heightened concen-
tration of plasma VEGF is characteristic of myxomas, such knowl-
edge might well lead to advances in diagnosis, management, fol-
low-up, and perhaps novel therapies to inhibit angiogenesis.3
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in accord with the findings of Kono and associates.1 They analyzed
myxomas and adjacent atrial myocardium from 15 patients, each
with a solitary tumor (13 left atrium, 2 right atrium) for VEGF pro-
tein expression and microvessel density. All tumors showed a pos-
itive immunohistochemical reaction for VEGF, whereas the adja-
cent atrial myocardium exhibited a negative reaction, indicating
that expression of the VEGF gene was confined to the tumor.
Tumors with the highest expression of VEGF showed the greatest
density of microvessels (angiogenesis), suggesting that it is VEGF
expression by the myxoma that induces and sustains angiogenesis
for tumor growth. 
Although expression of VEGF is characteristic of myxomas,
there is the question of sensitivity. What amount of tumor tissue
and/or gene expression is necessary to lift the plasma concentra-
tion of VEGF to a meaningful level? Not only was this woman’s
tumor multicentric, involving both sides of the heart, but the aggre-
gate tumor mass was greater than usually present with the typical
